Akebia reports data for its anemia drug candidate
Akebia Therapeutics Inc. (AKBA) reported top-line data from the second of its two global Phase 3 cardiovascular outcomes programs, PRO2TECT. The two studies were designed to assess the efficacy and safety of vadadustat in comparison to darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in adult patients not on dialysis.
Akebia reported that the drug candidate met its primary endpoint as well as key secondary efficacy endpoint in both the PRO2TECT studies. It showed non-inferiority to darbepoetin alfa as measured